Category - Markets

Markets

SVB Leerink starts Axcella Health at OP; PT $21

SVB Leerink initiated coverage of Axcella Health (NASDAQ:AXLA) with an “outperform” rating and a $21 price target. The stock closed at $14.27 on May 31.

June 3, 2019

Markets

Roth starts Atara Biotherapeutics at buy; PT $30

Roth Capital Partners launched coverage of Atara Biotherapeutics (NASDAQ:ATRA) with a “buy” rating and price target of $30. The stock closed at $23.30 on May 29.

May 31, 2019

Markets

Roth starts Marker Therapeutics at buy; PT $10

Roth Capital Partners initiated coverage of Marker Therapeutics (NASDAQ:MRKR) with a “buy” rating and $10 price target. The stock closed at $5.91 on May 29.

May 31, 2019

Markets

Roth starts Forty Seven at buy; PT $28

Roth Capital Partners initiated coverage of Forty Seven (NASDAQ:FTSV) with a “buy” rating and $28 price target. The stock closed at $12.49, up 34 cents, on May 28.

May 29, 2019

Markets

Roth starts Five Prime Therapeutics at neutral; PT $10

Roth Capital Partners launched coverage of Five Prime Therapeutics (NASDAQ:FPRX) with a “neutral” rating and $10 price target. The stock closed at $8.73, down 32 cents, on May 28.

May 29, 2019

Markets

Roth starts Corvus Pharma at buy; PT $6

Roth Capital Partners launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with a “buy” rating and price target of $6. The stock closed at $3.90 on May 28.

May 29, 2019

Markets

SVB Leerink transfers coverage of Alder BioPharma at OP; PT $21

Analyst Marc Goodman of SVB Leerink has assumed coverage of Alder BioPharmaceuticals (NASDAQ:ALDR) with an “outperform” rating and $21 price target. The stock closed at $11.06 on May 24.

May 28, 2019

Markets

Novo Holdings to acquire up to 10.1% in Oxford Biomedica

Novo Holdings A/S has agreed to invest up to £53.5 million in Oxford Biomedica plc (LSE:OXB) in return for new ordinary shares, representing up to 10.1% of the outstanding shares after a capital increase.

May 28, 2019

Markets

Canaccord starts TransMedics at buy; PT $37

Canaccord Genuity initiated coverage of TransMedics Group (NASDAQ:TMDX) with a “buy” rating and price target of $37. The stock closed at $28.88 on May 24.

May 28, 2019

Markets

Mackie Research cuts Medicure to hold; PT to $6.50 from $7.60

Mackie Research Capital downgraded Medicure (TSXV:MPH) to “hold from “buy” and cuts its price target to $6.50 from $7.60 after the company reported weaker than expected first quarter results. The stock closed at $5.99...

May 28, 2019

Category - Markets

SVB Leerink starts Axcella Health at OP; PT $21

Roth starts Atara Biotherapeutics at buy; PT $30

Roth starts Marker Therapeutics at buy; PT $10

Roth starts Forty Seven at buy; PT $28

Roth starts Five Prime Therapeutics at neutral; PT $10

Roth starts Corvus Pharma at buy; PT $6

SVB Leerink transfers coverage of Alder BioPharma at OP; PT $21

Novo Holdings to acquire up to 10.1% in Oxford Biomedica

Canaccord starts TransMedics at buy; PT $37

Mackie Research cuts Medicure to hold; PT to $6.50 from $7.60

General

More